New national Clinical Practice Guidelines for the Early Detection of Prostate Cancer have now been released, marking a major step forward in Australia’s approach to PSA testing and the early detection of prostate cancer.
Developed by Prostate Cancer Foundation of Australia and approved by the National Health and Medical Research Council, they establish a new national framework for risk assessment, shared decision-making, PSA testing, and contemporary diagnostic pathways designed to detect clinically significant prostate cancer earlier while reducing unnecessary tests and treatment.
Prostate cancer is the most commonly diagnosed cancer in Australia and remains one of the most significant health challenges facing Australian men and their families. The new Guidelines supersede the 2016 Clinical Practice Guidelines for PSA Testing, recognising that significant advances in evidence, diagnostic technology and clinical practice have created an opportunity for a more risk-based, structured and harm-minimising approach to early detection.
The Guidelines provide new guidance on when PSA testing should be offered, how frequently men should be tested, what PSA levels should prompt further investigation, the role of family history and inherited risk, the use of MRI before biopsy, and how GPs and specialists can support shared decision-making with patients.
For more information and support, please call 1800 22 00 99 or visit prostate.org.au.
HOST
Katie Clift
Director of International Public Relations Agency maybe, Global Moderator, Speaker & Breast Cancer Survivor
Katie Clift is Director of may:be, an international counter-cultural public relations agency. An MBA scholar of Warwick Business School. Katie has worked internationally on both sides of communications – in the media (radio, television & digital journalism) and as a PR, spokesperson, and corporate affairs executive - for both the private and public sectors. She has a decade of experience as a moderator, presenting sessions, interviews and press conferences globally, from the World Economic Forum in Davos to the Union for International Cancer Control’s World Cancer Congress and various in-person and online events. Katie was diagnosed with aggressive breast cancer in her 30s, and after 18 months of active treatment, returned to life and work more determined than ever to advocate for people affected by all types of cancer, and upscale communications for nonprofits globally.
GUESTS
Professor Jeff Dunn AO
Jeff is the Head of Research & Chief of Mission, Prostate Cancer Foundation of Australia; Professor of Social and Behavioural Science; and Chair of Cancer Survivorship, University of Southern Queensland; Immediate Past President, Union for International Cancer Control. In 2024 Professor Dunn was ranked by Stanford University as among the top 2% of scientists worldwide for oncology and clinical medicine confirming his status as an international leader in the social and behavioural aspects of cancer. Over the course of his 30-year career, Professor Dunn has pioneered patient-centred care, working across disciplines to build community capacity in cancer control, influencing local, national and global health policies and programs. His research has been published in more than 200 publications and Scival (2024) includes Prof Dunn as top three global high impact researchers in prostate cancer survivorship and quality of life. In 2014 Professor Dunn was appointed an Officer in the Order of Australia for distinguished service to medical administration through leadership of cancer control organisations and promotion of innovative and integrated cancer care programs.
Professor Jeremy Grummet
Professor Jeremy Grummet, MBBS MS FRACS, is a urologic surgeon and prostate cancer specialist. In 2025, he was named the top Australian researcher in Urology by The Australian newspaper. He is Director of Urology at Alfred Health and Professor of Surgery at Monash University. Professor Grummet has specific expertise in urological cancers and prostate cancer diagnosis, including MRI-targeted transperineal biopsy, prostate MRI and biopsy research, and contemporary diagnostic pathways for prostate cancer. He is a former European Association of Urology Guidelines Prostate Cancer Panel Member and Co-Founder of MRI PRO, an online prostate cancer diagnostic training platform.
Dr Michael Wright
Dr Michael Wright is President of the Royal Australian College of General Practitioners. He is a Sydney-based GP, health economist and health services researcher, and Associate Professor at the International Centre for Future Health Systems at the University of New South Wales. He combines clinical practice with academic research and strategic appointments focused on health policy, primary care quality and health system performance.
